Table 4.

Treatment outcomes of 200 adult non-L3 ALL patients, by karyotype and ploidy categories

Category	No. of patients	Complete remission		Resistant disease		Overall survival at 5 y*		Relapse-free survival at 5 y†		Disease-free survival at 5 y‡
		%	95% CI, %	%	95% CI, %	Est. %	95% CI, %	Est. %	95% CI, %	Est. %	95% CI, %
Normal diploid	31	87	70-96	10	2-26	50	32-68	43	24-62	64	39-89
t(9;22)/BCR/ABL1	36	67	49-81	19	8-36	8	2-22	0	0-14	0	0-34
Other unfavorable§	19	79	54-94	16	3-40	26	9-51	33	9-57	50	15-85
Miscellaneous	54	81	69-91	4	0-13	52	38-65	41	26-56	45	23-66
P‖¶		.21		.091		<.001		<.001		.006
Not evaluable	60	82	70-90	10	4-21	26	15-37	24	12-36	30	13-48
Normal diploid	31	87	70-96	10	2-26	50	32-68	43	24-62	64	39-89
Hypodiploid	11	73	39-94	27	6-61	24	0-51	38	4-71	—**	—
Pseudodiploid	45	78	63-89	4	1-15	42	27-56	39	23-55	58	34-82
Hyperdiploid	38	71	54-85	13	4-28	33	17-48	26	9-42	24	3-44
P‖#		.42		.18		.38		.82		.10
Other	6	83	36-100	17	0-64	17	0-64	0	0-52	—**	—
Not evaluable	69	83	72-91	10	4-20	24	14-34	20	10-31	26	11-42

Est. indicates estimated.

^*Five years after study entry.

^†Five years after complete remission.

^‡Five years after start of maintenance chemotherapy (maintenance patients only).

^§Other unfavorable is defined by the presence of −7, +8, and 11q23/MLL gene rearrangements.

^‖P values based on logistic (complete remission, resistant disease) or proportional hazards (overall survival, relapse-free survival, disease-free survival) regression analysis.

^¶P value for heterogeneity of outcomes among four categories with evaluable karyotype.

^#P value for heterogeneity of outcomes among four ploidy categories (normal, hypodiploid, pseudodiploid, and hyperdiploid).

^**DFS was not estimated for hypodiploid (N = 2) and other (N = 0) ploidy categories.